Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.5715 +0.0315 (+5.83%)
Streaming Delayed Price Updated: 2:33 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
31 32 Next >
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Discusses Biotech Industry Valuation Metrics
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria Discusses Valuation Metrics for Biotech Industry
Via ACCESSWIRE
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Bioscience' Tech Processed Cannabidiol Receives Positive FDA Feedback For Hypertension ↗
 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria Gets FDA's Positive Feedback On Pre-Clinical Trial Of Hypertension Candidate ↗
Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that it has received a positive full written response from the Food and Drug Administration (FDA) from its pre-Investigational New Drug meeting... 
Via Benzinga
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via Investor Brand Network
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill... 
Via FinancialNewsMedia
News headline image
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
Via ACCESSWIRE
The Power of Science to Stop a Killer
Via Investor Brand Network
The Power of Science to Stop a Killer
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114... 
Via FinancialNewsMedia
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Helping Innovators of Today, Leaders of Tomorrow
Via Investor Brand Network
Topics Cannabis Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Helping Innovators of Today, Leaders of Tomorrow
Via CannabisNewsWire
Topics Cannabis Intellectual Property
News headline image
Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗
 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events ↗
Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4 
Via Benzinga
News headline image
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
Via ACCESSWIRE
News headline image
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
KELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Supply Chain
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Notice of Allowance of 26th Worldwide Patent
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Notice of Allowance of 26th Worldwide Patent
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pending Start of Human Nicotine Study, NIC-H22-1, Leveraging Fast-Growing Global Nicotine Pouches Market
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners to Propel New, Exciting Growth Opportunities
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners to Propel New, Exciting Growth Opportunities
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications
Via CryptoCurrencyWire
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.